You are here
Wednesday, March 18, 2009
U.S. Cancer Screening Trial Shows No Early Mortality Benefit from Annual Prostate Cancer Screening
Six annual screenings for prostate cancer led to more diagnoses of the disease, but no fewer prostate cancer deaths, according to a major new report from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, a 17-year project of the National Cancer Institute (NCI), part of the National Institutes of Health. The PLCO was designed to provide answers about the effectiveness of prostate cancer screening.
"What this report tells us is that there may be some men who are diagnosed with prostate cancer and have the side-effects of treatment, such as impotence and incontinence, with little chance of benefit," said John E. Niederhuber, M.D., director of the NCI. "Clearly, we need a better way of detecting prostate cancer at its earliest stages and as importantly, a method of determining which tumors will progress. Many of the molecular studies we’re currently sponsoring will hopefully yield new, better ways of definitively classifying which men need treatment and which can consider watchful waiting. Until we have developed and verified a new test’s benefits and harms, as we have done with the PLCO, regular visits to your doctor to monitor your health are still strongly recommended."
Results appear online March 18, 2009, in the New England Journal of Medicine, to coincide with presentation of the data at the European Association of Urology meeting in Stockholm, Sweden. The print version of the results will appear in the March 26, 2009 issue.
NCI does not have a recommendation about prostate cancer screening. The U.S. Preventive Services Task Force, whose recommendations are considered the gold standard for clinical preventive services, recently concluded that there is insufficient evidence to assess the balance of benefits and harms of prostate cancer screening in men younger than age 75 and recommended against prostate cancer screening in men age 75 and older.
There were 76,693 men in the PLCO trial that was conducted at 10 centers around the United States. Of the men in the trial, 38,343 were randomly assigned to screening with annual prostate-specific antigen (PSA) tests for six rounds and digital rectal exams (DRE) for four rounds. A DRE is an exam whereby a doctor inserts a lubricated, gloved finger into the rectum and feels for anything that is not normal. The other 38,350 men were randomly assigned to usual care, but received no recommendations for or against annual prostate cancer screening.
Of those men who were screened annually, 85 percent had PSA tests and 86 percent had DREs. Men in the usual-care arm sometimes had these tests as well, due to the growing public acceptance of such screening. Screening by PSA in this usual-care group increased from 40 percent at the beginning of the study to 52 percent of men by the last screening year, and screening with DRE ranged from 41 percent initially to 46 percent by the last screening year. Men in the screening arm were referred to their usual health care provider for follow-up testing for prostate cancer if their PSA level was greater than 4.0 nanograms per milliliter (ng/mL) or if a DRE found an abnormality.
This report includes data for all participants at seven years after they joined the trial and for 67 percent of participants at 10 years after they joined the trial. Other important findings include:
At seven years, 22 percent more prostate cancers were diagnosed in the screening arm (2,820 men vs. 2,322 in the usual-care group). This excess is continuing to be observed in data collected up to 10 years (currently a 17 percent excess, 3,452 men vs. 2,974 men).
The vast majority of men in both groups who developed prostate cancer were diagnosed with relatively early stage II (out of IV stages, of which IV is late stage) disease, and the number of later-stage cases was similar in the two groups. However, using the Gleason scoring system, which assesses tumor aggressiveness, men in the usual-care group had more prostate cancers that fell into the Gleason 8 to10 range, which marks them as more aggressive. The smaller number of men with prostate cancer with a Gleason score of 8 to10 in the intervention group may eventually lead to a mortality difference between men in the two groups but data analyzed so far have not shown such a difference.
Men in both groups who were diagnosed with prostate cancer at the same stage received similar treatments for their disease. This reflects the PLCO study design policy of not mandating specific therapies
At seven years, 50 deaths were attributable to prostate cancer in the screening group and 44 deaths were attributable in the usual-care group. Through year 10, there were 92 prostate cancer deaths in the screening group and 82 in the usual-care group. The difference between the numbers of deaths in the two groups was not statistically significant. Thus there was no detectable mortality benefit for screening vs. usual-care.
Given the uncertainties about the mortality benefits of PSA testing, NCI has been pursuing many avenues to find new ways of screening for prostate cancer, including several sets of biomarkers that are being validated in its Early Detection Research Network (EDRN), some using specimens from PLCO’s biorepository of tissue and blood. Some examples of the marker tests include using microstrands of RNA to detect disease, examining changes in genes such as GSTP1, and imaging of proteins in prostate cancer tissue.
"NCI wants to understand why some prostate cancers are lethal even when found early by annual screening, and what approaches can be used to identify these more aggressive cancers when they can be effectively treated," said Christine Berg, M.D., NCI leader of the PLCO trial and senior author of the study. "The PLCO biorepository is an invaluable resource for such research, with nearly three million biological samples collected from our participants. Our hope is that through all aspects of the PLCO, we will gather the information that tells us whom to treat aggressively and whom to avoid overtreating."
Another report in this same online publication of the NEJM is from the large European Randomized Study of Screening for Prostate Cancer (ERSPC), which shows a 20 percent reduction in the rate of death from prostate cancer but with a high risk of overdiagnosis. In the ERSPC, unlike the PLCO trial, men were referred for follow-up testing if their PSA level was 3.0 ng/mL or higher and were also screened, on average, every four years as opposed to annually in the PLCO.
"Approaches such as lowering the threshold for what is considered an abnormal PSA level to 3.0 ng/mL will diagnose more cases, but it is not at all clear that it will identify the prostate cancers that are more likely to lead to a man’s death," said Berg.
The PLCO data are being made public now because the study’s Data and Safety Monitoring Board (DSMB), an independent review committee that meets every six months, saw a continuing lack of evidence that screening reduces death due to prostate cancer as well as the suggestion that screening may cause men to be treated unnecessarily. The DSMB also supports continued follow up of all participants so that every participant is tracked for at least 13 years from entry onto the trial.
The PLCO is a large-scale clinical trial, sponsored and run by NCI's Division of Cancer Prevention, begun in 1992 to determine whether certain cancer screening tests can help reduce deaths from prostate, lung, colorectal and ovarian cancer. The underlying rationale for the trial is that screening for cancer may enable doctors to discover and treat the disease earlier.
Nearly 155,000 women and men between the ages of 55 and 74 have joined the PLCO trial. At entry, participants were assigned at random to one of two study groups: One group received routine health care from their health providers. The other received a series of exams to screen for prostate, lung, colorectal, and ovarian cancers. Screening of participants ended in late 2006. Follow-up of participants is anticipated to continue for several more years.
A call-in teleconference will be held on Tuesday, March 17, 2009 at 12:00 p.m. (noon) EDT to discuss the implications of this finding and to answer reporter questions about these results. This teleconference is only for credentialed reporters who agree to abide by the embargo policies of the NEJM. To register for the teleconference and receive call-in information, please contact a NCI press officer at either (301) 496-6641 or firstname.lastname@example.org by 9:00 a.m. EDT on Tuesday, March 17.
A Q&A on the prostate screening results from the PLCO is available at http://www.cancer.gov/newscenter/pressreleases/PLCOprostateResultsQandA.
A new issue of NCI’s BenchMarks, related to cutting-edge prostate cancer treatment issues, will be available March 19, 2009 at http://www.cancer.gov/newscenter/benchmarks-vol8-issue1.
NCI leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI Web site at http://www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®